


Next-level metastatic breast cancer monitoring



Consideration may be given to spacing out imaging and using the DiviTum® TKa test as an aid in-between imaging

“It is interesting to learn that the DiviTum® TKa test can identify progression many months ahead of imaging.”³

Luca Malorni, MD, PhD
Medical Oncologist, Prato Hospital, Italy



Using a small blood sample, the DiviTum® TKa test can aid in prognosis and monitoring post-menopausal women with HR+ advanced breast cancer.

The DiviTum® TKa test measures TK activity as a surrogate for cell proliferation and tumor growth.

Complement and Better Inform Monitoring

In postmenopausal female patients with metastatic HR+ breast cancer; a low value is associated with the decreased likelihood of disease progression within 30 days or 60 days post testing.^{1,2}

DiviTum® TKa provides clinically meaningful information for patients with HR+ MBC. Low TKa levels provide such a high NPV for rapid progression that such patients might forego additional therapy added to single agent ET.²

1) Paoletti et al., Clin Cancer Res. 2021 Nov 15;27(22):6115-6123

2) Mattias Bergqvist, et al. (2023) Biomarkers, DOI: 10.1080/1354750X.2023.2168063

3) Krishnamurthy, J., et al. npj Breast Cancer 8, 35 (2022).

Budget Impact Analysis⁴

Objective: “To estimate the diagnostic and treatment budget impact of the (DiviTum® TKa) assay...”

Results: “Expected savings approached 3x the spend on the new test. Results were most sensitive to DiviTum® TKa cost, population parameters, and treatment costs.”

”...savings approached 3x the spend on the new test”

Conclusion: “Clinical use of the DiviTum® TKa assay is expected to decrease traditional imaging and monitoring and may reduce the overall cost of managing mBC if it leads to clinical decisions to avoid futile therapy.”

4) Carlson J, et. al. (2021) 24:1, 1309-1317, DOI: 10.1080/13696998.2021.2003674

DiviTum® TKa test: Complements Imaging and Other Blood-Based Tumor Markers

- Imaging may not be convenient for the patient, or it may be equivocal in non-measurable disease (up to 40% of HR+ mBC patients have non-measurable disease⁵), in bone-only disease, lobular breast cancer, in patients with reduced kidney function, or in mixed response situations.
- Conventional biomarkers – such as CA 15-3 – are not expressed in all women with mBC.⁶

5) Larsson AM, et al. Sci Rep. 2020;10(1):4484

6) Gaughran G, et al. Breast Cancer Management, 2023 <https://doi.org/10.2217>

DiviTum® TKa is CE labeled in Europe and FDA 510(k) cleared in the United States. The DiviTum® TKa method and kit are protected under US Patent Nos. 8,765,378 and 9,376,707.

Patent protection in 49 countries

DiviTum® is a registered trademark of Biovica International AB

©Biovica International AB 2023. All rights reserved.



Clinical Studies



Distributed by:
Axlab A/S
+45 35 43 18 81
axlab@axlab.dk
www.axlab.dk

Axlab

YOUR VISION.
OUR INSPIRATION

BI+OVICA®

Dag Hammarskjölds väg 54B
Uppsala Science Park 752 37 Uppsala, Sweden
info@biovica.com

@Biovica